Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis

Rheumatology International

Volumn 27, Issue 11, 2007, Pages 1063-1069

  Osiri, Manathip ^a   Kamolratanakul, Pirom ^a   Maetzel, Andreas ^b   Tugwell, Peter ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cost effectiveness analysis; Disease modifying antirheumatic drugs; Health assessment questionnaire; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; DAPSONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; THAILAND;

EID: 34547839643     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0342-5     Document Type: Article

References (35)

1. Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(suppl 1):1-12
2. Meenan RF, Yelin EH, Henke CJ et al (1978) The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum 21:827-833
3. Meenan RF, Yelin EH, Nevitt M, Epstein WV (1981) The impact of chronic disease. A sociomedical profile of rheumatoid arthritis. Arthritis Rheum 24:544-549
4. Lubeck DP, Spitz PW, Fries JF et al (1986) A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 29:488-493
5. van Jaarsveld CH, Jacobs JW, Schrijvers AJ et al (1998) Effects of rheumatoid arthritis on employment and social participation during the first years of disease in the Netherlands. Br J Rheumatol 37:848-853
6. Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis Rheum 42:1209-1218
7. Michaud K, Messer J, Choi HK, Wolfe F (2003) Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 48:2750-2762
8. Merkesdal S, Ruof J, Schoffski O et al (2001) Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 44:528-534
9. Lajas C, Abasolo L, Bellajdel B et al (2003) Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 49:64-70
10. Pugner KM, Scott DI, Holmes JW, Hieke K (2000) The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 29:305-320
11. Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39:28-33
12. Suarez-Almazor ME, Osiri M, Emery P, Ottawa Methods Group (2004) Rheumatoid arthritis. In: Tugwell P, Shea B, Boers M et al (eds) Evidence-based rheumatology. BMJ Publishing Group, London, pp 243-282
13. Gabriel SE, Coyle D, Moreland LW (2001) A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 19:715-728
14. Thompson MS, Read JL, Hutchings HC et al (1988) The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 15:35-42
15. Borg G, Allander E, Goobar JE (1990) Disease-modifying antirheumatic drug therapy: an expensive therapy despite inexpensive drugs. Scand J Rheumatol 19:115-121
16. Prashker MJ, Meenan RF (1995) The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 38:318-325
17. Kavanaugh A, Heudebert G, Cush J, Jain R (1996) Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 25:297-307
18. Anis AH, Tugwell PX, Wells GA, Stewart DG (1996) A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 23:609-613
19. Verhoeven AC, Bibo JC, Boers M et al (1998) Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 37:1102-1109
20. Choi HK, Seeger JD, Kuntz KM (2000) A cost-effectiveness analysis of treatment options for methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 43:2316-2327
21. Maetzel A, Strand V, Tugwell P et al (2002) Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomized controlled trial. Pharmacoeconomics 20:61-70
22. Maetzel A, Strand V, Tugwell P et al (2002) Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 47:655-661
23. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:15-24
24. Osiri M, Deesomchok U, Tugwell P (2001) Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the health assessment questionnaire. Rheumatology 40:555-558
25. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137-145
26. Heston A, Summers R, Aten B (2002) Penn World Table version 6.1. Center for International Comparisons at the University of Pennsylvania (CICUP).
27. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 update Arthritis Rheum 46:328-346
28. Carmichael SJ, Beal J, Day RO, Tett SE (2002) Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 29:2077-2083
29. O'Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287-1291
30. O'Dell JR, Haire CE, Erikson N et al (1996) Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 23(Suppl 44):72-74
31. O'Dell J, Paulsen G, Haire C et al (1998) Combination DMARD therapy with methotrexate-sulfasalazine-hydroxychlo-roquine in rheumatoid arthritis: continued efficacy with minimal toxicity at 5 years (abstract). Arthritis Rheum 41(Suppl 9):S132
32. O'Dell JR, Leff R, Paulsen G et al (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164-1170
33. Kobelt G, Jonsson L, Young A, Eberhardt K (2003) The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42: 326-335
34. Welsing PM, Severens JL, Hartman M et al (2004) Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 51:964-973
35. Brennan A, Bansback N, Reynolds A, Conway P (2004) Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43:62-72